KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBITDA (2018 - 2025)

Historic EBITDA for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$173.4 million.

  • Vir Biotechnology's EBITDA rose 2501.51% to -$173.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.6 million, marking a year-over-year increase of 992.95%. This contributed to the annual value of -$587.2 million for FY2024, which is 1419.54% up from last year.
  • As of Q3 2025, Vir Biotechnology's EBITDA stood at -$173.4 million, which was up 2501.51% from -$118.4 million recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's EBITDA peaked at $1.0 billion during Q1 2022, and registered a low of -$231.3 million during Q3 2024.
  • Its 5-year average for EBITDA is -$23.6 million, with a median of -$139.5 million in 2025.
  • The largest annual percentage gain for Vir Biotechnology's EBITDA in the last 5 years was 73910.28% (2022), contrasted with its biggest fall of 46911.35% (2022).
  • Quarter analysis of 5 years shows Vir Biotechnology's EBITDA stood at $571.8 million in 2021, then plummeted by 126.32% to -$150.5 million in 2022, then rose by 7.63% to -$139.0 million in 2023, then increased by 15.73% to -$117.2 million in 2024, then crashed by 48.05% to -$173.4 million in 2025.
  • Its EBITDA stands at -$173.4 million for Q3 2025, versus -$118.4 million for Q2 2025 and -$139.5 million for Q1 2025.